Deeper & Broader Impact Across B-Cell Malignancies With Ubx-303-1, A First-In-Class Btk/Hck/Lyn Degrader in Phase 1a
- Exploring how UBX-303-1 is a first-in-class, oral BTK/HCK/LYN degrader in Phase 1a for B-cell malignancies, demonstrating complete tumor regression in preclinical models and early signs of tumor response in the clinic
- Discussing how UBX-303-1 addresses key unmet medical needs by overcoming BTK inhibitor resistance in CLL and has the potential to introduce an oral treatment option for DLBCL patients
- Outlining how Ubix is advancing beyond CRBN-based degraders, expanding into Degrader-Antibody Conjugates (DACs) and novel E3 ligase binders